Abstract Malignant gliomas are diffusively infiltrative and remain among the deadliest of all cancers. NF-jB is a transcription factor that mediates cell growth, migration and invasion, angiogenesis and resistance to apoptosis. Normally, the activity of NF-jB is tightly regulated by numerous mechanisms. However, in many cancers, NF-jB is constitutively activated and may function as a tumor promoter. Herein, we show that in gliomas, NF-jB is constitutively activated and the levels of cIAP2, Bcl-2, BclxL and Survivin are elevated. These genes are regulated by NF-jB and can inhibit apoptosis. To understand the potential role of NF-jB p65 in suppressing apoptosis, we generated human glioma cell lines that inducibly express shRNA molecules specific for p65. We demonstrate that in the absence of p65, TNF-a induced cIAP2 expression is significantly reduced while the levels of Bcl-2, Bcl-xL and Survivin are not affected. These data suggest that of these genes, only cIAP2 is a direct target of p65, which was confirmed using RT-PCR and chromatin immunoprecipitation (ChIP) assays. By reducing the levels of p65 and/or cIAP2 levels, we demonstrate that the levels of RIP polyubiquitination are reduced, and that p65-deficient glioma cells are more sensitive to the cytotoxic effects of TNF-a. Specifically, in the presence of TNF-a glioma cells lacking p65 and/or cIAP2 showed cellular proliferation defects and underwent cell death. These data suggest that NF-jB and/ or cIAP2 may be therapeutically relevant targets for the treatment of malignant gliomas.
Introduction
The NF-jB proteins are a family of five transcription factors; RelA/p65, RelB, c-Rel, p105/p50 and p100/p52 [1] . Each member of this family contains a Rel homology domain, which allows them to homo-and heterodimerize in nearly every permutation possible. Additionally, the C-terminus of p65, RelB and c-Rel contains a transactivation domain (TAD), which allows NF-jB dimers that contain p65, RelB or c-Rel to positively regulate transcription. In the central nervous system (CNS) and other cell types, the most common NF-jB dimer consists of p65 and p50, and this form is specifically referred to as NF-jB [2] [3] [4] . Normally, NF-jB is inactive and maintained in the cytosol through interactions with Inhibitor of NF-jB alpha (IjBa), which binds to NF-jB and masks its DNA binding domain and nuclear localization signal. NF-jB is activated in response to numerous stimuli, which activate the IjB kinase (IKK) complex. IKK phosphorylates IjBa, which targets it for proteasomal mediated degradation. Once released, the NF-jB dimer translocates to the nucleus, where it binds to specific DNA sequences, known as jB elements, to induce the expression of numerous genes. To date, hundreds of NFjB target genes have been identified, which mediate various processes including cell growth, angiogenesis, cell migration and invasion, and resistance to apoptosis [5] .
Malignant gliomas are aggressive, neurologically destructive and deadly tumors of the CNS [6, 7] . When possible, gliomas are debulked through surgical resection [8, 9] . However, because of their diffusive nature and localization, this treatment is limited and the tumor often recurs at the original or distant sites [6] [7] [8] . Attempts to improve patient survival have utilized radiotherapy and/or chemotherapy [9, 10] . However, gliomas remain notoriously resistant to chemo-and immunotherapies, and the current goal of adjuvant therapy is to prolong the patient's survival in a clinically good condition, since eradication of the disease remains highly unlikely.
In gliomas, NF-jB is constitutively activated [11] [12] [13] and is associated with apoptotic resistance and poor disease prognosis [14] [15] [16] . Previous studies with glioma cells have shown that the use of either a dominant-negative form of NF-jB or a non-degradable form of IjBa increased apoptosis in response to TNF-a and chemotherapeutic agents [17] [18] [19] . Additionally, non-specific inhibitors of NF-jB activation such as sulfasalazine and curcumin have also been shown to inhibit glioma cell growth and increase sensitivity to apoptosis [20, 21] . The ability of NF-jB to mediate resistance to apoptosis may depend on its ability to induce one or more target genes. In fibrosarcoma cells, NFjB induced expression of TNF-a receptor-associated factor 1 (TRAF1), TRAF2, cellular Inhibitor of Apoptosis 1 (cIAP1) and cIAP2 were requisite to mediate resistance to TNF-a induced apoptosis [22] . In T cells, TNF-a was shown to induce cIAP2 expression, and this was sufficient to inhibit TNF-a induced cell death [23] . However, in gliomas, the specific role of one NF-jB family member, p65, and its role in mediating resistance to cell death, remains unclear.
Members of the cIAP family, which include cIAP1, cIAP2, Survivin, X-linked Inhibitor of Apoptosis (XIAP) and BIR-containing ubiquitin-conjugating enzyme (BRUCE), are structurally similar proteins that minimally contain at least one Baculoviral IAP Repeat (BIR) domain [24] . Most cIAP proteins also contain a C-terminal RING domain that enables them to function as E3 ubiquitin ligases [24, 25] , while cIAP1 and 2 also contain a caspase recruitment domain (CARD), whose function is not yet clear [24] . The cIAP proteins are potent inhibitors of apoptosis, although the mechanism(s) remain poorly understood. Interestingly, cIAP1, cIAP2 and XIAP have all been shown to bind to caspases, yet only XIAP is capable of directly inhibiting caspase activity [26] [27] [28] . Instead, it is postulated that cIAP proteins may inhibit apoptosis largely through their intrinsic ubiquitin ligase activity [24] . Thus far, cIAP1 can auto-ubiquitinate itself and trans-ubiquitinate both XIAP and cIAP2 in order to regulate the overall levels of cIAP proteins. Additionally, both cIAP1 and cIAP2 can transubiquitinate receptor interacting protein 1 (RIP1) [29] [30] [31] . RIP1 is a serine/threonine kinase that interacts with death receptors such as TNF receptor 1 (TNFR1) [30] . Upon binding to TNF-a, the TNFR1 recruits several proteins including TRADD, TRAF2, cIAP1, cIAP2 and RIP1, which culminates in RIP1 becoming lysine 63-linked (K63-linked) poly-ubiquitinated [31] . When poly-ubiquitinated, RIP1 recruits two additional kinases, IKK and TAK1, which mediate the activation of NF-jB and promote cell survival [31] . In the absence of cIAP1 and cIAP2, RIP1 is still recruited to the TNFR1 but fails to become poly-ubiquitinated. As a consequence, the non-ubiquitinated RIP1 protein binds to and activates caspase 8, thus re-routing TNF-a signaling towards a pro-apoptotic pathway [29] .
In gliomas, it remains unclear whether constitutively activated NF-jB induces the expression of genes that mediate resistance to TNF-a induced cell death. In the present study, we demonstrate that in gliomas, NF-jB is constitutively activated and the levels of cIAP2, Bcl-2, BclxL and Survivin are elevated. Using human glioma cells that were engineered to inducibly express shRNA molecules specific for p65, we addressed the role of NF-jB in regulating the expression of these proteins, and their potential role(s) in mediating resistance to TNF-a induced cell death. In the presence of NF-jB p65, TNF-a induced cIAP2 expression, which was abrogated upon the loss of p65 expression. In contrast, the loss of endogenous p65 protein levels did not affect the levels of Bcl-2, Bcl-xL or Survivin, suggesting these genes are not totally dependent on NF-jB p65 for expression. Additionally, we show that glioma cells with reduced p65 and cIAP2 levels express lower levels of poly-ubiquitinated RIP1, and were re-sensitized to the cytotoxic effects of TNF-a. As such, these data suggest that NF-jB p65 and cIAP2 may be key targets in developing novel therapeutic strategies to overcome apoptotic resistance in gliomas.
Materials and methods

Reagents
Recombinant human TNF-a was purchased from R&D Systems (Minneapolis, MN). Secondary peroxidase-conjugated antibodies were purchased from Amersham (Arlington Heights, IL). ECL reagents were purchased from Pierce (Rockford, IL). Antibodies specific for p65, c-Rel, RelB, p105/p50, p100/p52, Survivin, IjBa, ubiquitin, TRAF2, TRADD, RIP1 and cIAP1, and normal rabbit serum were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies specific for caspase 8 and phosphorylated-p65 (S536) were purchased from Cell Signaling Technology (Danvers, MA). Anti-cIAP2 antibody was purchased from BD Pharmingen (San Jose, CA). Anti-p65 antibody for chromatin immunoprecipitation (ChIP), and antibodies specific for GAPDH and caspase 3 were obtained from Abcam (Cambridge, MA). Monoclonal antibodies specific for Bcl-2 and Bcl-xL were a generous gift of Dr. Tong Zhou (University of Alabama at Birmingham).
Plasmids
A plasmid encoding shRNA specific for p65 was generated by annealing double stranded oligonucleotides specific for a 19 bp region of the p65 ORF (CTG TTC CCC CTC ATC TTC C) into the plasmid, pBABE-HI-TetO, which is under the dual control of the tet operator and the HI Pol III promoter. The plasmid, pBABE-HI-TetO, was a generous gift of Dr. Xinbin Chen (University of California, Davis). The U251-MG glioma cell line was obtained from ATCC, and maintained as previously described [32] . U251-MG cells that stably express the Tet repressor (TetR) protein (U251-TR) and U251-TR cells that inducibly express shRNA specific for p65 (sh-p65) (U251-TR/sh-p65) were generated as previously described [12] . Plasmids encoding shRNA specific for cIAP2 or cIAP1 were generated by annealing double stranded oligonucleotides specific for cIAP2 or cIAP1 into pLVX-shRNA2 (Clontech, Palo Alto, CA). Lentiviral molecules expressing shRNA molecules specific for cIAP2 or cIAP1 were generated using the Lenti-X-HT kit and used according to manufacturer's instructions (Clontech, Palo Alto, CA).
Human control and glioma tissues
Resected non-malignant (control) and malignant (glioma) brain tissue was obtained from the UAB Brain Tumor Tissue Core facility (IRB X050415007), snap-frozen in liquid nitrogen, and stored at -80°C until processed. Tissues were ground with liquid nitrogen in a pre-chilled mortar and pestle at 4°C as previously described [12] . The ground tissue was collected and processed using the PARIS kit according to the manufacturer's instructions (Ambion, Austin, TX). Protein was analyzed by immunoblotting, and RNA was analyzed by RT-PCR as previously described [12] .
Immunoblotting
Where indicated, U251-TR/sh-p65 cells were grown in the absence (-) or presence (?) of Tet (4 lg/ml) for 24 h. Cells were then incubated in serum free media (SFM) in the absence or presence of Tet for 24 h and/or TNF-a (10 ng/ml) for the times indicated. Protein concentrations were measured using BioRad Assay and equal amounts of total protein were analyzed by SDS-PAGE using the antibodies specified, as previously described [12] . Immunoprecipitation U251-TR/sh-p65 cells were grown in the absence (-) or presence (?) of Tet for 24 h. Cells were then incubated in SFM in the absence or presence of Tet for 24 h. Next, cells were left untreated (-) or treated (?) with TNF-a (10 ng/ ml) for the times indicated. Cells were washed twice in cold PBS and collected in ice cold RIPA. Protein concentrations were measured using BioRad Assay and equal amounts of total protein were pre-cleared using protein A/G beads, and then subjected to immunoprecipitation using anti-RIP1 antibodies overnight at 4°C. The next day, protein A/G beads were added for 2 h at 4°C. Immunoprecipitated complexes were washed three times with RIPA buffer and analyzed by immunoblot assays using antibodies specific for ubiquitin.
Total RNA isolation and reverse transcriptase-PCR (RT-PCR)
Where indicated, U251-TR/sh-p65 cells were grown in the absence (-) or presence (?) of Tet for 24 h. Cells were then incubated in SFM in the absence or presence of Tet for 24 h and/or TNF-a (10 ng/ml) for various times. Total RNA was isolated as previously described [33] . Two lg of total RNA was reverse transcribed and analyzed by PCR using primers specified. For quantitative real-time PCR (qRT-PCR), the following primers/probe sets were purchased from Applied Biosystems (Foster City, CA): IjBa (Hs00153283_m1), cIAP1 (Hs00236911_m1), cIAP2 (Hs00985031_g1), and 18s (Hs99999901_s1). Reactions for each sample were performed in triplicate using an ABI StepOnePlus Detection System (Applied Biosystems, Foster City, CA) and a PCR protocol comprising an initial 10 min incubation at 95°C followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. The raw data were analyzed using StepOnePlus software (Applied Biosystems) and DDCt values for each gene in each sample were determined.
ChIP
ChIP assays were performed as previously described [12, 33, 34] . Five lg of appropriate antibody was used to immunoprecipitate proteins of interest. Immune complexes were precipitated with protein A beads (Millipore, Billirica, MA) blocked with BSA and salmon sperm DNA. Immunoprecipitated DNA was subjected to semi-quantitative PCR using primers specific for the cIAP2 promoter. PCR products were analyzed by gel electrophoresis. To detect the cIAP2 promoter, the following primers were used: cIAP-Pro- Growth rate analyses
To determine the rate of cell growth, cells were seeded at approximately 6 9 10 4 cells/60-mm plate in the absence or presence of Tet for 48 h. Next, the medium was replaced and cells were grown in the absence or presence of Tet and/ or TNF-a (10 ng/ml). The medium was replaced every 72 h. At times indicated, three plates per condition were rinsed twice with PBS to remove dead cells and debris. Live cells on the plates were trypsinized and collected separately. Cells from each plate were counted three times using the Coulter cell counter. The average number of cells from three plates was used for growth rate determination [35, 36] .
DNA histogram analyses
Cells were seeded at 2 9 10 5 per 90-mm plate in the absence or presence of Tet for 48 h. Next, the medium was changed and cells were grown in the absence or presence of Tet and/or TNF-a. At the times indicated, both floating and dead cells in the medium and live cells on the plate were collected and fixed with 5 ml of 100% ethanol for 4 h and then centrifuged, washed twice with PBS and resuspended in 300 ll of PBS solution containing 50 lg/ml each of RNase A (Sigma) and propidium iodide (Sigma). The stained cells were analyzed in a fluorescence-activated cell sorter (FACS) (FACSCaliber, Becton-Dickinson) within 4 h. The percentage of cells in sub-G1, G1, S, and G2-M phases was determined using the Cell Quest program and ModFit program. The percentage of cells in sub-G1 phase was used as an index for the degree of cell death [35, 36] .
WST-1 cell proliferation and viability assay
Cells were seeded at 1 9 10 4 cells per well in a 96-well plate in complete media in the absence or presence of Tet. At 24 h, cells were grown in SFM in the absence or presence of Tet for an additional 24 h. Next, cells were grown in SFM in the absence or presence of Tet and/or TNF-a (10 ng/ml) for 24 h. Cell proliferation, viability and mitochondrial metabolic activity were measured using the WST-1 assay kit according to the manufacturer's instructions (Clontech, Mountain View, CA).
Statistical analysis
Where presented, values represent the mean ± standard deviation. Levels of significance for comparison between samples were determined by the Student's t-test distribution. p values of less than or equal to 0.05 were considered to be statistically significant.
Results
NF-jB is elevated and constitutively activated in gliomas
Previously, we have shown that NF-jB is constitutively activated in gliomas [12] . To extend this finding, we evaluated the status of NF-jB proteins in 10 non-malignant ( Fig. 1, control ; lanes 1-10) and 12 malignant glioma (glioma; lanes 11-22) samples. All control tissues displayed moderate levels of total p65, while p65 levels were elevated in nine of 12 glioma tissues. To assess NF-jB activation, we performed immunoblot assays using antibodies specific for p65 phosphorylated on serine residue 536 (p-p65 (S536)), which is correlated with transcriptional activation [37] . Although basal levels of p-p65 (S536) were detected in the control tissues, these levels were elevated in 11 of 12 glioma samples evaluated ( Fig. 1) . In control tissues, the levels of p50 varied amongst samples and appeared elevated in several glioma tissues. These results demonstrate that NF-jB is elevated and constitutively activated in gliomas.
Anti-apoptotic proteins regulated by NF-jB are overexpressed in gliomas NF-jB regulates the expression of several anti-apoptotic genes, including cIAP2, Survivin, Bcl-2, Bcl-xL and cIAP1 [38] [39] [40] [41] . To address whether these proteins were elevated in gliomas, we performed immunoblot analyses. As shown in Fig. 1 , in control tissues, the levels of Survivin, Bcl-2 and Bcl-xL expression were low or absent while cIAP1 and cIAP2 were moderately expressed in all. Except for cIAP1, the levels of these proteins were elevated in gliomas. To confirm these data in a larger sample population, we analyzed the expression of cIAP2, Survivin, Bcl-2 and Bcl-xL mRNA levels using Oncomine, a cancer microarray database [42] . In a comparison of 981 samples, we determined that the levels of cIAP2, cIAP1, Bcl-xL and Survivin mRNA were elevated in glioblastoma compared to control brain (P \ 2.35 9 10 -4 , P \ 4.43 9 10 -6 and P \ 7.11 9 10 -14 , respectively) [42, 43] . The levels of Bcl-2 and cIAP1 mRNA varied between and within glioblastoma and control brain tissues (P-values ranged from 0.005 to 0.967 and 0.457 and 0.893, respectively). These data suggest that in gliomas, NF-jB is activated and the levels of cIAP2, Bcl-xL and Survivin are elevated.
Generation of glioma cells that inducibly regulate endogenous p65 levels
In the CNS, the most common NF-jB dimer consists of p65 and p50, and of these two subunits, only p65 contains a TAD [2] [3] [4] . Therefore, to directly address the role of NF-jB in mediating apoptotic resistance in gliomas, we generated human glioma cell lines that inducibly expressed shRNA molecules specific for p65 (U251-TR/sh-p65) [12] . To evaluate the efficacy of p65 shRNA expression and determine the time needed to maximally reduce endogenous p65 protein levels, U251-TR/sh-p65 cells were grown in the absence (-) or presence of Tet (?) for various times and protein levels analyzed by immunoblot assays. The levels of endogenous p65 protein are noticeably diminished at 31 h post-Tet, are nearly absent at 48 h and this effect persists until at least 72 h (Fig. 2a) . To address whether the expression of p65 shRNA affected the levels of other NFjB family members, U251-TR/sh-p65 cells were grown in the absence (-) or presence (?) of Tet for 48 h and protein expression analyzed by immunoblot analyses. We determined that neither the expression of p65 specific shRNA molecules, nor the absence of p65 affected the expression of additional NF-jB family members (Fig. 2b) . To determine whether reductions in endogenous p65 protein levels were sufficient to inhibit the expression of an NF-jB target gene, we analyzed the expression of IjBa. In the absence of Tet or TNF-a, both p65 and IjBa proteins were detected (Fig. 2c, lanes 1 and 5) . In the presence of Tet, the levels of p65 are reduced and the levels of IjBa protein were unaffected (lanes 2 and 6). Upon stimulation with TNF-a, the levels of IjBa are reduced by degradation within 30 min (lane 3), and this was not altered by the absence of endogenous p65 (lane 4). At 60 min post-TNF-a, IjBa protein levels were nearly restored in cells that express p65 (lane 7), and this was blocked in cells that lacked p65 protein (lane 8). To confirm these data, we analyzed IjBa by qRT-PCR. In the absence of Tet or TNF-a, modest levels of IjBa mRNA were detected, and these levels were slightly reduced in the presence of Tet alone (Fig. 2d ). Upon treatment with TNF-a, the levels of IjBa mRNA were significantly increased at 2 h, and remained elevated until 24 h. However, in the absence of p65, the levels of IjBa mRNA were significantly reduced at each time point assessed (*P \ 0.05). These data demonstrate that the loss of p65 is sufficient to prevent TNF-a-induced IjBa mRNA and protein expression.
Absence of p65 reduces cIAP2 expression but not Bcl-2, Bcl-xL or Survivin expression To assess how the loss of p65 protein impacts cIAP2, Bcl-2, Bcl-xL and Survivin expression, U251-TR/sh-p65 cells were grown in the absence (-) or presence (?) of Tet for 48 h to reduce endogenous p65 levels, then in the absence or presence of TNF-a for 12 or 24 h, and protein levels analyzed by immunoblot assays. Because human glioma cells in culture are not subject to the same microenvironment as tumors, TNF-a was added to mimic the environment and ensure NF-jB activation. In the absence of Tet or TNF-a, U251-MG glioma cells constitutively expressed Bcl-2, Bcl-xL and Survivin but did not express cIAP2 (Fig. 3a, lanes 1 and 5) . Interestingly, the levels of Bcl-2, Bcl-xL and Survivin were relatively unchanged in the absence of p65 (lanes 2 and 6), TNF-a (lanes 3 and 7), or both (lanes 4 and 8). In contrast, TNFa induced expression of cIAP2 at 12 h (lane 3) and these levels remained elevated at 24 h (lane 7). However, in the absence of p65, TNF-a induced cIAP2 expression was inhibited (lanes 4 and 8). These results indicate that NFjB p65 is required for the maximal expression of cIAP2 by TNF-a. Fig. 1 NF-jB is constitutively activated in human gliomas and correlates with elevated levels of anti-apoptotic genes. Thirty micrograms of total protein from fresh snap-frozen brain tissue resected from nonmalignant (Control) or patients diagnosed with gliomas (Glioma) were evaluated by immunoblotting using antibodies specific for total p65, phospho-p65 (p-p65(S536)), p50, cIAP2, Survivin, Bcl-2, Bcl-xL, cIAP1 and GAPDH. Representative of three experiments J Neurooncol (2011) 102:367-381 371
Above, we show that cIAP2 expression is sensitive to the presence or absence of p65 protein. Because others have reported that cIAP1 can also be regulated by NF-jB, we also evaluated the levels of cIAP1 protein in these cells [22] . U251-TR/sh-p65 cells were grown in the absence or presence of Tet for 48 h, and then stimulated with TNF-a for various times. Total protein was collected and evaluated by immunoblot analyses. As shown in Fig. 3b , in the absence of Tet or TNF-a, cIAP1, but not cIAP2, protein was detected (lane 1), and the levels of cIAP1 were not affected by diminished p65 expression (lane 2). Upon TNF-a stimulation, the levels of cIAP2 protein were slightly increased at 2 h (longer exposure, data not shown) and noticeably increased at later time points (lanes 5, 7, 9 and 11). TNF-a induced cIAP2 expression was blocked by reductions in p65 expression (lanes 6, 8, 10 and 12). In contrast, the presence of TNF-a alone had no effect on cIAP1 protein levels (compare lane 1 with lanes 3, 5, 7, 9 and 11). However, in those cells that lacked p65, the protein levels of cIAP1 were slightly reduced at 6 h (compare lanes 5 and 6) and nearly absent at 24 h (compare lanes 11 and 12) post-TNF-a stimulation. Collectively, these data indicate that cIAP2 expression is dependent on NF-jB p65, and that in the absence of NF-jB p65, prolonged TNF-a stimulation may reduce the levels of cIAP1 protein. Next, we used qRT-PCR to confirm that cIAP2 mRNA expression is dependent on NF-jB p65. In the absence of any stimuli or in the presence of Tet alone, the levels of cIAP2 mRNA were very low (Fig. 3c) . cIAP2 mRNA levels were substantially increased at 2, 6, 8, 12, 18 and 24 h post-TNF-a stimulation. In the absence of p65, the levels of cIAP2 mRNA were significantly reduced (*P \ 0.05). These data confirm that NF-jB is required for maximal cIAP2 mRNA expression in response to TNF-a in U251-MG cells.
To confirm that cIAP2 is a direct transcriptional target of NF-jB p65, U251-TR/sh-p65 cells were grown in the absence or presence of Tet and/or TNF-a, and ChIP assays were performed using antibodies specific for p65. In the absence of any stimulus or in the presence of Tet alone, p65 was not detected at the cIAP2 promoter (Fig. 3d, lanes  1 and 2) . After 1 h of TNF-a stimulation, p65 was detected at the cIAP2 promoter (lane 3), and these levels were reduced in the presence of Tet (lane 4). These data confirm cIAP2 is a direct transcriptional target of NF-jB p65, and that NF-jB p65 is required for maximal induction of cIAP2 in response to TNF-a stimulation.
RIP1 is hypo-ubiquitinated upon TNF-a stimulation in the absence of p65
Thus far, our data suggest that in the absence of p65, TNFa fails to induce cIAP2 expression. Previous studies demonstrated that cIAP1 and cIAP2 mediate the K63-linked ubiquitination of RIP1, which consequently allows RIP1 to interact with the pro-survival kinases TAK1 and IKK [29] . Therefore, we hypothesized that in the absence of p65, U251-MG cells that were challenged with TNF-a may display reduced levels of RIP1 ubiquitination. To address this, U251-TR/sh-p65 cells were grown in the absence or presence of Tet for 48 h and then in the absence or presence of TNF-a for various times. Whole cell extracts were collected and equal amounts of proteins were immunoprecipitated with antibodies specific for RIP1 and then analyzed by immunoblot assays using antibodies specific for ubiquitin. In the absence of any stimuli, these cells display low levels of ubiquitinated RIP1 (Poly-Ub RIP1) (Fig. 4a, lane 1 Fig. 3 TNF-a induced cIAP2 expression is dependent on NF-jB p65. a U251-TR/sh-p65 cells were grown in the absence or presence of Tet for 48 h, and then in the absence or presence of TNF-a for 12 or 24 h. Total proteins were analyzed by immunoblot analyses using the antibodies specified. b U251-TR/sh-p65 cells were grow in the absence or presence of Tet for 48 h and then in the absence or presence of TNF-a for various times. Total proteins were analyzed using the antibodies specified. c U251-TR/sh-p65 cells were grown in the absence or presence of Tet for 48 h, and then in the absence or presence of TNF-a for various times. Total RNA was analyzed by qRT-PCR using primers specific for cIAP2. Results have been normalized to 18s expression and the values presented represent average RQ ± SD (*P \ 0.05). Representative of three experiments. d U251-TR/sh-p65 cells were grown in the absence or presence of Tet for 48 h, and then in the absence or presence of TNF-a for 1 h. ChIP assays were performed using antibodies specific for p65 or control IgG. Input and IP DNA was analyzed using primers specific for human cIAP2 promoter. Representative of five experiments J Neurooncol (2011) 102:367-381 373 4). In the presence of TNF-a, the levels of Poly-Ub RIP1 increased in a time dependent manner until 40 min post-TNF-a (lanes 5, 7, and 9), and were reduced at 50 min (lane 11). However, in the absence of p65, the levels of Poly-Ub RIP1 were substantially reduced at 20-50 min post-TNF-a stimulation (Fig. 4a, lanes 6, 8, 10 and 12 ). To assess whether changes in the expression levels of either cIAP1 or cIAP2 correlated with the diminished levels of Poly-Ub RIP1, mRNA was collected from U251-TR/sh-p65 cells grown in the absence or presence of Tet, and the absence or presence of TNF-a for 0, 5, 15, or 30 min and analyzed by qRT-PCR (Fig. 4b) . At 30 min post-TNF-a, the levels of cIAP2 mRNA (grey bars) were significantly enhanced and these levels were reduced in the absence of p65. Although the basal levels of cIAP1 mRNA (white bars) were reduced in the absence of p65 alone, TNF-a stimulation and/or the presence of p65 did not significantly alter the levels of cIAP1 mRNA. Additionally, no significant changes in the levels of cIAP1 protein were observed during this time period (data not shown).
D C
To determine if these results were due to differences in total RIP1 levels, or the levels of TRAF2 and TRADD, which are also present at the TNF-a receptor, we analyzed their expression using immunoblot assays. As shown in Fig. 4c , the levels of endogenous p65 were reduced by the presence of Tet. However, neither the absence nor presence of Tet and/or TNF-a altered the levels of TRAF2, TRADD or RIP1, suggesting that the results of Fig. 4a were due to changes in the levels of Poly-Ub RIP1.
Reduced NF-jB p65 levels do not impair cell growth but do reduce glioma cell growth in response to TNF-a In the absence of p65, U251-MG cells challenged with TNFa failed to express cIAP2 and harbored reduced levels of poly-Ub RIP1. Therefore, because the ubiquitinated status of RIP1 determines whether TNF-a signaling is pro-survival or pro-apoptotic, we assessed the effects of reduced p65 and cIAP2 expression on cell proliferation in the absence or presence of TNF-a. These cells provided a suitable model since U251-MG cells are resistant to the cytostatic effects of TNF-a. U251-TR/sh-p65 cells were grown in the absence or presence of Tet for 48 h to reduce p65 expression, then grown in the absence or presence of Tet and/or TNF-a and growth rate analyses were performed. As shown in Fig. 5a , cells grown in the absence of any stimulus (filled diamond) or in the presence of Tet (filled square) alone displayed similar growth rates. The addition of TNF-a alone (filled triangle) had only a modest effect on cell growth after 5 days, while those cells grown in the presence of Tet and TNF-a (filled Fifty lg total protein were evaluated by immunoblot analyses using antibodies specific for TRAF2, TRADD, RIP1, p65 and GAPDH circle) were significantly impaired in their ability to grow. These data indicate that TNF-a impairs glioma growth in the absence of p65 expression.
TNF-a induces cell death in glioma cells that lack p65 expression
To assess whether the negative effects of TNF-a on glioma cell growth were due to cell cycle inhibition or cell death, DNA histogram analyses were performed. U251-TR/shp65 cells were grown in the absence or presence of Tet for 48 h to reduce p65 protein levels, and then in the absence or presence of Tet and/or TNF-a for an additional 24 h. In the absence of Tet or TNF-a, approximately 60% of U251-MG cells were in G1, 15% in S, 20% in G2-M and 5% were undergoing cell death (sub-G1) (Fig. 5b) . The percentage of cells in each phase of the cell cycle was not altered by the presence of Tet or TNF-a. However, cells grown in the presence of Tet and TNF-a showed modest reductions in the percentage of cells in G1, S and G2-M, while the percentage of cells undergoing cell death (sub-G1) increased to approximately 25% (Fig. 5b) . Next, we evaluated cIAP2 levels and caspase activation by immunoblot assays. U251-TR/sh-p65 cells were grown in the absence or presence of Tet for 48 h, and then in the absence or presence of Tet and/or TNF-a for 12 or 24 h. 5 TNF-a impairs cell growth and induces cell death in the absence of NF-jB p65. a U251-TR/sh-p65 cells were grown in the absence or presence of Tet for 48 h, and then in the absence or presence of TNF-a for an additional 5 days. Each day, cells were washed, trypsinized and the number of cells was counted using a Coulter Counter. Medium ± Tet ± TNF-a was changed at 3 and 6 days of the experiment. Data points represents the mean ± SEM of three independent measurements per plate, and three plates per condition were evaluated. *P \ 0.001 when compared to TNF-a alone. b U251-TR/sh-p65 cells were grown in the absence or presence of Tet for 48 h, and then in the absence or presence of TNF-a for 24 h. At 72 h after plating, both floating and dead cells in the media and live cells on the plates were collected and were fixed with 5 ml of 100% ethanol overnight and were then centrifuged and resuspended in 300 ll of PBS solution containing 50 lg each of RNase A and propidium iodide per ml. The stained cells were measured by FACS analysis. The percentage of cells in the sub-G1, G1, S, and G2-M phases was determined by using the Cell Quest program. The percentage of cells in the sub-G1 phase was used as an index for the degree of cell death. Columns represent the mean ± SEM of three independent experiments. *P \ 0.002 when compared with TNF-a alone. c U251-TR/sh-p65 cells were grown in the absence or presence of Tet for 48 h, and then in the absence or presence of TNF-a for 12 or 24 h. Whole cell lysates were collected and the levels of procaspase 8, cleaved caspase 8, pro-caspase 3, cleaved caspase 3, cIAP2, p65 and GAPDH were analyzed using the antibodies specified. d U251-TR/sh-p65 cells were grown in the absence or presence of Tet for 48 h and then in the absence or presence of TNF-a for 24 h. Mitochondrial metabolic activity was measured using the WST-1 assay according to the manufacturer's instructions. Representative of five experiments. **P \ 0.005 when compared with all other treatments J Neurooncol (2011) 102:367-381 375
We did not detect cIAP2 expression, or activation of caspase-8 or caspase-3 in cells grown in the absence of any stimulus (Fig. 5c, lane 1) or in the presence of Tet alone (lane 2). Although TNF-a alone increased the levels of cIAP2 and caused modest activation of caspase-8 at 12 and 24 h, we failed to detect concomitant activation of caspase-3 (lanes 3 and 5). However, cells grown in both Tet and TNF-a displayed reduced levels of cIAP2 concommittant with caspase-8 and caspase-3 activation (lanes 4 and 6). Finally, to confirm the incidence of cell death, we assessed the metabolic activity of mitochondria in U251-TR/sh-p65 cells in the absence or presence of Tet and/or TNF-a. Cells were grown as described above, and then evaluated using the WST-1 assay, a derivative of the MTT assay. In this assay, cells are provided a tetrazolium salt, which can be cleaved by mitochondrial succinate-tetrazolium reductase to yield a soluble formazan dye. The activity of this enzyme and the amount of soluble formazan dye released are directly proportional to the number of viable cells [44] . As shown in Fig. 5d , cells left untreated or treated with either Tet or TNF-a alone displayed similar metabolic activities. However, those cells treated with Tet and TNF-a exhibited a significant reduction in mitochondrial activity (**P \ 0.005). Collectively, these data indicate that TNF-a induces cell death in glioma cells that lack p65 expression.
Loss of cIAP2 sensitizes gliomas to cell death induced by TNF-a Our data suggest that in gliomas, TNF-a fails to induce cell death, in part through NF-jB-induced cIAP2 expression and perhaps destabilized cIAP1 protein levels. Indeed, when NF-jB p65 is removed from glioma cells, cIAP2 fails to be expressed, and when challenged with TNF-a, these cells ultimately reduce the levels of cIAP1 protein and undergo cell death. To demonstrate that these results are dependent on cIAP2 expression, parental U251-MG cells, which express endogenous p65, were left untransduced (-), transduced with a control lentivirus (C), or a lentivirus expressing shRNA molecules specific for cIAP2 (cIAP2). These cells were allowed to recover for 4 days, grown in the absence or presence of TNF-a for 24 h, and then p65 and cIAP2 levels assessed by immunoblotting. As shown in Fig. 6a , U251-MG cells containing NF-jB p65 do not express cIAP2 unless challenged with TNF-a (compare lanes 1 and 2), and this was not affected by the introduction of control lentiviral molecules (lanes 3 and 4) . However, in the presence of lentiviral expressed cIAP2 shRNA molecules, TNF-a induced cIAP2 levels were significantly reduced (compare lanes 2 and 6). To assess whether the reductions in cIAP2 levels were sufficient to induce caspase activation, we evaluated the levels of procaspase 8 and cleaved caspase 8 in these samples. In U251-MG cells, TNF-a did not induce caspase 8 activation in untransduced cells or cells transduced with control lentivirus (Fig. 6a, lanes 2 and 4) . However, in U251-MG cells transduced with lentivirus expressing cIAP2 shRNA, TNF-a induced caspase 8 cleavage (lane 6). These data suggest that TNF-a activates NF-jB and induces cIAP2 to prevent cell death in glioma cells.
To confirm that the reduced cIAP2 expression can sensitize U251-MG cells to TNF-a induced cell death, we measured the metabolic activity of mitochondria. Cells were grown as described above, and then evaluated using the WST-1 assay. The mitochondrial metabolic activity of cells left untransduced (-), transduced with control virus (C) or transduced with lentivirus expressing shRNA specific for cIAP2 were comparable in the absence of TNF-a (Fig. 6b, white bars) . Upon TNF-a stimulation, the , transduced with control lentivirus (C) or lentivirus expressing shRNA molecules specific for cIAP2 (cIAP2) and allowed to recover for 4 days. Cells were then left untreated (-) or treated (?) with TNF-a for 24 h. Whole cell lysates were collected and the levels of cIAP2, p65, pro-caspase 8, cleaved caspase 8 and GAPDH were analyzed using the antibodies specified.
Representative of two experiments. b U251-MG cells were grown as described in a, and mitochondrial metabolic activity was measured using the WST-1 assay according to the manufacturer's instructions.
Representative of six experiments. *P \ 0.05 when compared to untransduced, unstimulated cells. **P \ 0.005 when compared to untransduced, TNF-a stimulated cells metabolic activity of mitochondria increased in untransduced or control transduced cells (grey bars). However, in those cells transduced with lentivirus expressing shRNA specific for cIAP2, TNF-a stimulation significantly reduced the metabolic activity of mitochondria compared with untreated (*P \ 0.05) and/or TNF-a treated (**P \ 0.005) parental U251-MG cells. These data indicate that NF-jB induced cIAP2 expression is required to protect glioma cells from TNF-a induced cell death.
Discussion
Although neither a classical tumor suppressor nor an oncogene, the role for NF-jB in tumors is quickly becoming the focus of much attention. Increasing evidence supports a role for NF-jB and inflammation in mediating several facets of tumor behavior, including cell growth, migration, invasion, angiogenesis and resistance to apoptosis [1, 45] . In gliomas, we and others have shown that NF-jB is constitutively activated, and that the levels of many NF-jB regulated genes are elevated [11, 12, 46] . At present, the exact mechanism(s) underlying NF-jB activation remains poorly understood, but may be in part explained by the tumor microenvironment, the loss of negative regulators and/or the presence of elevated levels of positive regulators. For example, in the CNS, TNF-a is secreted by microglia, astrocytes and some neurons [47] . Although TNF-a can signal through two receptors, in gliomas, the levels of TNFR1 are elevated compared to normal brain tissues [48, 49] . Therefore, in gliomas, TNF-a signaling through TNFR1 favors NF-jB activation and promotes tumor growth and development [50] [51] [52] . NF-jB may also be activated by numerous growth factors or signaling pathways that are dysregulated in gliomas. NF-jB is activated by epidermal growth factor (EGF), which is frequently amplified, and/or its receptor, EGFR, which is often mutated and constitutively activated [7] . Many gliomas also show allelic loss or down-regulation of PTEN, a tumor suppressor and negative regulator of the AKT pathway. In the absence of PTEN expression, AKT is constitutively active and can activate NF-jB [7] . We have recently shown that ING4, a negative regulator of NF-jB, is expressed at very low levels or is mutated in GBMs, and that the lack of ING4 enables NF-jB to remain constitutively active [12] . Conversely, Pin1, a positive regulator of NF-jB, is overexpressed in GBMs [53, 54] , and also contributes to NF-jB activation [53] . Therefore, there is a strong correlation between constitutive NF-jB activation and gliomagenesis [55] . Human gliomas are notoriously resistant to apoptosis. In the present study, we investigated what role, if any, a single NF-jB family member, p65, plays in mediating apoptotic resistance to TNF-a. We focused on p65 as our studies showed that this protein is overexpressed and constitutively activated in human gliomas compared to non-glioma samples (Fig. 1) . Additionally, we determined that the levels of cIAP2, Survivin, Bcl-2 and Bcl-xL were also elevated in gliomas. Each of these genes can be regulated by NF-jB and can inhibit apoptosis. Therefore, because NF-jB is known to be constitutively activated in gliomas and can induce these genes, we hypothesized that NF-jB and one or more of these gene(s) were responsible for suppressing TNF-a induced cell death in gliomas. To address this, we engineered human glioma cells that inducibly expressed shRNA molecules specific for p65 (U251-TR/sh-p65) so that we could regulate the levels of endogenous p65 protein, and thus measure the cellular response to TNF-a (Fig. 2) . Interestingly, Survivin, Bcl-2 and Bcl-xL were constitutively expressed in U251-MG cells and their expression was unchanged by the absence or presence of p65 or TNF-a. In contrast, cIAP2 expression was absent in U251-MG cells, yet in the presence of p65, TNF-a increased the levels of cIAP2, and this was impaired in cells that lacked p65 (Fig. 3a, b) . Moreover, in U251-MG cells, which constitutively express cIAP1, prolonged exposure (24 h) to TNF-a reduced the levels of cIAP1 protein and this was enhanced by the loss of p65 protein (Fig. 3b) . Using qRT-PCR and ChIP assays, we confirmed that cIAP2 is a direct transcriptional target of NF-jB p65, and that in the absence of p65, TNF-a fails to sufficiently induce cIAP2 expression or recruit NF-jB p65 to the cIAP2 promoter. Thus, our data confirm that cIAP2 is a direct transcriptional target of NF-jB p65 and is induced in response to TNF-a. cIAP1 and cIAP2 each contain an E3 ubiquitin ligase domain and have been shown to target RIP1 for K63-linked ubiquitination [29] (Fig. 7a) . When ubiquitinated, RIP1 associates with IKK and TAK1, which activate NF-jB [29] . In the absence of ubiquitination, RIP1 associates with and activates pro-caspase 8, which leads to caspase 3 activation and apoptosis [29] (Fig. 7b) . Therefore, the ubiquitination status of RIP1 is critical in determining whether TNF-a signaling is pro-survival or pro-apoptotic. Thus far, our data suggest that gliomas inevitably favor NF-jB activation, and consequently, NF-jB ensures the levels of cIAP2 are elevated. We provide data demonstrating that TNF-a-induced RIP1 ubiquitination occurs independently of NF-jB p65 within 10 min of TNF-a, since the loss of endogenous p65 did not reduce the levels of RIP1 ubiquitination (Fig. 4a, lanes 1-4) . However, the levels of poly-ubiquitinated RIP1 after 10 min of TNF-a appear dependent on p65 expression, since these levels are dramatically reduced if p65 expression is reduced/absent (Fig. 4a, lanes 5-12) . We can speculate that the basal and early phase of TNF-a induced RIP1 poly-ubiquitination (0-10 min) may rely on cIAP1, whose short-term expression is not sensitive to p65. However, we propose that the inducible phase of RIP1 poly-ubiquitination is dependent on cIAP2, whose expression pattern is both consistent within this time frame (Fig. 4b) and dependent on p65 (Figs. 3a-c, 4b) . Therefore, in gliomas, where cIAP1 is expressed and cIAP2 is constitutively expressed and elevated (Fig. 1) , it is possible that RIP1 is hyper-ubiquitinated and thus this would allow TNF-a signaling, by default, to be pro-survival in these tumors. We are currently exploring these possibilities to test our hypothesis.
Moreover, our data suggest that NF-jB-induced cIAP2 expression, and perhaps the destabilization of cIAP1, are key upstream events that promote cell survival, and that reductions in cIAP2 and/or cIAP1 expression, either indirectly, through reductions in p65 levels (Fig. 5 ), or directly, by preventing cIAP2 expression (Fig. 6) , can reroute TNF-a signaling towards an apoptotic end (Fig. 7) . Therefore, we propose that in gliomas, cIAP1 is responsible for basal RIP1 poly-ubiquitination. Moreover, constitutively activated NF-jB mediates resistance to cytotoxic stimuli by increasing or stabilizing the levels of cIAP2, and perhaps cIAP1, which further ensures RIP1 remains polyubiquitinated, in order to promote a pro-survival signaling pathway (Fig. 7a) . However, in the absence of NF-jB p65 (Fig. 7b) , prolonged TNF-a stimulation destabilizes the levels of cIAP1 and cIAP2 fails to be expressed, consequently leading to hypo-ubiquitinated RIP1. The hypoubiquitinated RIP1 associates with and activates caspase 8, which initiates the apoptotic cascade. Secreted TNF-a molecules bind to the death receptor TNFR1. Associated with the cytoplasmic portion of TNFR1 are several adaptor molecules including TRADD, TRAF2 and the serine/threonine kinase RIP1, which may be ubiquitinated (orange circles) by cIAP1. Upon TNF-a stimulation, RIP1 is further poly-ubiquitinated by newly synthesized cIAP2. This ensures RIP1 interacts with and activates the kinases IKK and TAK1. These kinases then phosphorylate the inhibitory protein IjBa, which targets it for ubiquitinmediated degradation. In the absence of IjBa, the newly released NF-jB molecule, p65/p50, is free to move into the nucleus and induce the expression of genes that mediate pro-survival. In particular, NF-jB upregulates the expression of cIAP2, which poly-ubiquitinates RIP1 during pathophysiological conditions to ensure that TNF-a signaling promotes a pro-survival pathway. b Pro-apoptotic TNF-a signaling. TNF-a binds to TNFR1, which interacts with TRADD, TRAF2 and RIP1. Immediately before and after TNF-a binding, RIP1 remains poly-ubiquitinated, and perhaps competent to activate IKK and/or TAK1, since IjBa still undergoes proteolytic degradation. However, in the absence of p65 and a transcriptionally active NF-jB complex, the levels of cIAP1 appear to become destabilized (dashed lines) and cIAP2 fails to be expressed. As a consequence of this, the levels of poly-ubiquitinated RIP1 rapidly diminish (light orange circles) and pro-caspase 8 interacts with and becomes activated by hypo-ubiquitinated RIP1. Once activated, caspase 8 activates additional caspases, which execute the ensuing phases of cell death What does this mean in terms of therapeutic potential for gliomas? These findings underscore the importance of targeting NF-jB and/or cIAP2 and potentially other cIAP family members (as discussed below) as therapeutically relevant strategies for gliomas and other cancers. Herein, we show that NF-jB is constitutively activated in human gliomas and that reductions in NF-jB p65 levels can resensitize glioma cells to the cytotoxic effects of TNF-a. This is consistent with other studies that have also shown increased cell death in glioma models by chemotherapies and/or radiation if NF-jB activity is simultaneously blocked [56] [57] [58] [59] [60] [61] [62] [63] . However, since inhibiting global NF-jB activity may be undesirable and/or specifically targeting NF-jB activity in gliomas may be difficult, we propose that identifying and targeting those genes that mediate particular facets of NF-jB behavior might be a more reasonable goal.
Members of the IAP family regulate whether the cell lives or dies in response to numerous stresses and insults. This is because the IAP proteins are the only endogenous proteins thus far identified that can regulate the activity of both initiator and effector caspases [64] . As such, IAP proteins have garnered attention lately, specifically as pharmacological targets in the development of therapeutic strategies in various cancers. In vivo, second mitochondriaderived activator of caspases, direct IAP-binding protein with low pI (Smac/DIABLO) is a mitochondrial protein. In the presence of apoptotic signals, Smac/DIABLO is cleaved and released into the cytoplasm, where it antagonizes the activity of IAP proteins [64] . Thus far, Smac/DIABLO appears to inhibit all IAP proteins except NAIP, and minimally requires the first four amino terminal residues of the cleaved cytoplasmic protein (Ala-Val-Pro-Ile) in order to inhibit IAP proteins and activate caspases [64] . Studies based on how this tetrapeptide of Smac/DIABLO recognizes and binds to IAP proteins have lead to the development of small molecules and prototypical drugs that would function analogously to cytoplasmic Smac/DIABLO [64] . Thus far, these compounds have shown very promising results in reducing tumor burden and prolonging survival time in numerous studies both in vitro and in vivo [64] . Indeed, several pharmaceutical and biotechnology companies have currently active programs developing Smac mimetics, with some compounds already in clinical trials [64] . While data from these studies are sparse, increasing interest in the NF-jB family and IAP members continue to reinforce our belief that these proteins are key targets with therapeutic potential in fighting apoptotic resistance in gliomas, and perhaps other types of neoplasia.
